Celgene Corporation (CELG) Shares Sold by Gamco Investors INC. ET AL
Gamco Investors INC. ET AL lowered its stake in Celgene Corporation (NASDAQ:CELG) by 17.2% in the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 10,529 shares of the biopharmaceutical company’s stock after selling 2,180 shares during the quarter. Gamco Investors INC. ET AL’s holdings in Celgene Corporation were worth $1,367,000 at the end of the most recent quarter.
Other hedge funds also recently bought and sold shares of the company. Harel Insurance Investments & Financial Services Ltd. bought a new stake in Celgene Corporation in the first quarter worth about $118,000. Acropolis Investment Management LLC bought a new stake in Celgene Corporation in the second quarter worth about $144,000. Mitsubishi UFJ Securities Holdings Co. Ltd. raised its position in Celgene Corporation by 47.5% in the first quarter. Mitsubishi UFJ Securities Holdings Co. Ltd. now owns 1,180 shares of the biopharmaceutical company’s stock worth $147,000 after acquiring an additional 380 shares in the last quarter. Rational Advisors LLC bought a new stake in Celgene Corporation in the second quarter worth about $156,000. Finally, Oakworth Capital Inc. raised its position in Celgene Corporation by 11.7% in the second quarter. Oakworth Capital Inc. now owns 1,216 shares of the biopharmaceutical company’s stock worth $158,000 after acquiring an additional 127 shares in the last quarter. 79.24% of the stock is owned by institutional investors and hedge funds.
Shares of Celgene Corporation (NASDAQ CELG) opened at 137.17 on Thursday. The company has a 50 day moving average price of $141.25 and a 200 day moving average price of $130.39. The company has a market cap of $107.31 billion, a PE ratio of 42.48 and a beta of 1.88. Celgene Corporation has a 52 week low of $96.93 and a 52 week high of $147.17.
Celgene Corporation (NASDAQ:CELG) last announced its earnings results on Thursday, July 27th. The biopharmaceutical company reported $1.82 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $1.61 by $0.21. Celgene Corporation had a return on equity of 68.51% and a net margin of 21.35%. The business had revenue of $3.27 billion for the quarter, compared to analyst estimates of $3.23 billion. During the same quarter last year, the firm earned $1.44 EPS. Celgene Corporation’s revenue for the quarter was up 18.7% compared to the same quarter last year. On average, equities analysts expect that Celgene Corporation will post $7.32 earnings per share for the current year.
CELG has been the topic of several research reports. BidaskClub upgraded shares of Celgene Corporation from a “sell” rating to a “hold” rating in a research report on Wednesday, June 21st. Leerink Swann reiterated an “outperform” rating on shares of Celgene Corporation in a research report on Thursday, June 22nd. William Blair reiterated an “outperform” rating on shares of Celgene Corporation in a research report on Monday, June 26th. BTIG Research cut shares of Celgene Corporation from a “buy” rating to a “neutral” rating and boosted their price target for the stock from $96.93 to $131.70 in a research report on Friday, June 30th. Finally, Vetr upgraded shares of Celgene Corporation from a “hold” rating to a “strong-buy” rating and set a $149.76 price target on the stock in a research report on Tuesday, July 4th. Two analysts have rated the stock with a sell rating, five have assigned a hold rating and twenty-two have assigned a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and an average target price of $151.53.
In related news, insider Terrie Curran sold 1,727 shares of Celgene Corporation stock in a transaction that occurred on Monday, September 25th. The stock was sold at an average price of $143.89, for a total value of $248,498.03. Following the sale, the insider now owns 3,925 shares of the company’s stock, valued at approximately $564,768.25. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Gilla Kaplan sold 7,500 shares of Celgene Corporation stock in a transaction that occurred on Wednesday, August 2nd. The shares were sold at an average price of $134.52, for a total value of $1,008,900.00. Following the completion of the sale, the director now directly owns 76,301 shares in the company, valued at approximately $10,264,010.52. The disclosure for this sale can be found here. In the last three months, insiders sold 46,233 shares of company stock worth $6,268,259. 0.95% of the stock is owned by insiders.
Celgene Corporation Profile
Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.
Want to see what other hedge funds are holding CELG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Celgene Corporation (NASDAQ:CELG).
Receive News & Ratings for Celgene Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.